Your browser doesn't support javascript.
loading
Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.
Lossos, Chen; Liu, Yunpeng; Kolb, Kellie E; Christie, Amanda L; Van Scoyk, Alexandria; Prakadan, Sanjay M; Shigemori, Kay; Stevenson, Kristen E; Morrow, Sara; Plana, Olivia D; Fraser, Cameron; Jones, Kristen L; Liu, Huiyun; Pallasch, Christian P; Modiste, Rebecca; Nguyen, Quang-De; Craig, Jeffrey W; Morgan, Elizabeth A; Vega, Francisco; Aster, Jon C; Sarosiek, Kristopher A; Shalek, Alex K; Hemann, Michael T; Weinstock, David M.
Afiliación
  • Lossos C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Liu Y; Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
  • Kolb KE; MIT Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts.
  • Christie AL; Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
  • Van Scoyk A; Institute for Medical Engineering and Science (IMES), Department of Chemistry, and Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
  • Prakadan SM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
  • Shigemori K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Stevenson KE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Morrow S; Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
  • Plana OD; Institute for Medical Engineering and Science (IMES), Department of Chemistry, and Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts.
  • Fraser C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
  • Jones KL; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Liu H; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Pallasch CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Modiste R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Nguyen QD; John B. Little Center for Radiation Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Craig JW; Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Department of Systems Biology, Harvard Medical School, Boston, Massachusetts.
  • Morgan EA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Vega F; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Aster JC; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
  • Sarosiek KA; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Shalek AK; Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hemann MT; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Weinstock DM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Cancer Discov ; 9(7): 944-961, 2019 07.
Article en En | MEDLINE | ID: mdl-31040105
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Ciclofosfamida / Alquilantes / Alemtuzumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfoma de Células B / Ciclofosfamida / Alquilantes / Alemtuzumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Cancer Discov Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos